Author

J. M. Trent

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 4 Research Focus:drug response / drug discovery· 3 Assay:proteomics· 3 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Approach:statistical model· 1

Frequent Co-Authors

A. N. Karnezis· 4 shared B. E. Weissman· 4 shared D. G. Huntsman· 4 shared P. Pirrotte· 4 shared Y. Wang· 4 shared E. A. Raupach· 3 shared J. D. Lang· 3 shared K. A. Orlando· 3 shared

Activity by Year

2017-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

A. N. Karnezis

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Landscape of super-enhancers in small cell carcinoma of the ovary, hypercalcemic type and efficacy of targeting with natural product triptolide

J. D. Lang, W. Selleck, S. Striker, N. A. Hipschman, R. Kofman, A. N. Karnezis, F. K. Kommoss, F. Kommoss, J. R. Wendt, S. J. Facista, W. P. Hendricks, K. A. Orlando, P. Pirrotte, E. A. Raupach, V. L. Zismann, , J. M. Trent

This paper identifies super-enhancer activity in SCCOHT driven by SMARCA4 loss and shows triptolide effectively inhibits tumor growth by targeting TFIIH at super-enhancers.

iScience · Feb 1, 2025Peer-reviewedCancer Biology

Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients

S. Wong, E. Ehrhart, S. Stewart, V. Zismann, J. Cawley, R. Halperin, N. Briones, K. Richter, K. Sivaprakasam, N. Perdigones, T. Contente-Cuomo, S. Facista, J. M. Trent, M. Murtaza, C. Khanna, W. P. D. Hendricks

This study examines genomic heterogeneity in canine splenic hemangiosarcoma, identifying driver mutations and intratumoral diversity across multiple regions.

bioRxiv · Nov 15, 2020Cancer Biology

Arginine depletion through ADI-PEG20 to treat argininosuccinate synthase deficient ovarian cancer, including small cell carcinoma of the ovary, hypercalcemic type

J. X. Ji, D. R. Cochrane, B. Tessier-Cloutier, S. Chen, G. Ho, K. V. Pathak, I. Alcazar, D. Farnell, S. Leung, A. Cheng, C. Chow, S. Colborne, G. Luca Negri, F. Kommoss, A. N. Karnezis, , D. G. Huntsman

This paper identifies ASS1 deficiency in rare ovarian cancers and shows that ADI-PEG20 inhibits tumor growth in ASS1-deficient models.

bioRxiv · Nov 17, 2019 · PreprintCancer Biology

Novel functional insights revealed by distinct protein-protein interactions of the residual SWI/SNF complex in SMARCA4-deficient small cell carcinoma of the ovary, hypercalcemic type

E. A. Raupach, K. Garcia-Mansfield, R. Sharma, A. M. Hegde, V. David-Dirgo, Y. Wang, C. Young Shin, L. V. Tao, S. J. Facista, R. Moore, J. D. Lang, V. L. Zismann, K. A. Orlando, M. Spillman, A. N. Karnezis, , P. Pirrotte

This study identifies distinct protein-protein interactions of the residual SWI/SNF complex in SMARCA4-deficient SCCOHT cell lines, revealing altered functional consequences and potential synthetic lethal targets.

bioRxiv · Oct 6, 2019 · PreprintCancer Biology

Ponatinib shows potent antitumor activity in small cell carcinoma of the ovary hypercalcemic type (SCCOHT) through multi-kinase inhibition

J. D. Lang, W. P. D. Hendricks, H. Yin, J. Kiefer, P. Ramos, R. Sharma, P. Pirrotte, E. A. Raupach, C. Sereduk, N. Tang, W. S. Liang, M. Washington, S. J. Facista, V. L. Zismann, E. M. Cousins, , J. M. Trent

This paper identifies ponatinib as a potent treatment for SCCOHT by inhibiting multiple kinases in preclinical models.

bioRxiv · Jul 6, 2017Cancer Biology